Upping the Game
The conversation at this year’s ASCO sessions in some of the less sought after cancers carried an undercurrent of cautious optimism rarely heard in these halls.

Time for some new pathways and fresh directions
After decades of incremental progress and sobering statistics, investigators are grappling with an unexpected problem: how to sequence, combine, and optimise a sudden influx of active agents targeting pathways, which actually seem to matter.
The familiar old refrain of “nothing works in X!” is giving way to more complex questions about biomarker selection and maintenance strategies.
It’s entirely possible we’re finally approaching the critical mass of effective therapies needed to fundamentally alter the disease trajectories.
Yet beneath this enthusiasm lies a nagging awareness of how the most challenging aspects of these cancers remain untouched by our expanding arsenal.
In this review, we explore a number of different agents showing early promise, which may offer opportunities for intrepid companies seeking to make a real difference…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers